U.S. markets closed
  • S&P Futures

    3,840.50
    +12.50 (+0.33%)
     
  • Dow Futures

    31,423.00
    +52.00 (+0.17%)
     
  • Nasdaq Futures

    12,851.25
    +19.50 (+0.15%)
     
  • Russell 2000 Futures

    2,191.80
    -8.20 (-0.37%)
     
  • Crude Oil

    63.27
    -0.26 (-0.41%)
     
  • Gold

    1,771.60
    -3.80 (-0.21%)
     
  • Silver

    27.47
    -0.22 (-0.79%)
     
  • EUR/USD

    1.2180
    -0.0006 (-0.05%)
     
  • 10-Yr Bond

    1.5180
    +0.1290 (+9.29%)
     
  • Vix

    28.89
    +7.55 (+35.38%)
     
  • GBP/USD

    1.4014
    +0.0001 (+0.01%)
     
  • USD/JPY

    105.9000
    -0.3300 (-0.31%)
     
  • BTC-USD

    46,977.46
    -3,781.04 (-7.45%)
     
  • CMC Crypto 200

    935.66
    -59.00 (-5.93%)
     
  • FTSE 100

    6,651.96
    -7.01 (-0.11%)
     
  • Nikkei 225

    29,425.69
    -742.58 (-2.46%)
     

Exicure Announces Presentation at 2021 H.C. Wainwright Global Life Sciences Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced that CEO David Giljohann will present at the 2021 H.C. Wainwright Global Life Sciences Conference, March 9-10, 2021.

The presentation will be available to registered conference attendees for on-demand viewing beginning March 9, 2021 at 7:00AM EST via the virtual conference link, and will be archived for 90 days.

Exicure will be taking 1x1 investor meetings with registered conference attendees.

Replays of the presentation will be available on Exicure’s website for 30 days following the presentation.

About Exicure, Inc.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN an SNA–based therapeutic candidate, for the treatment of Friedreich’s ataxia (FA). Exicure's drug candidate AST-008 is currently in a Phase 1b/2 clinical trial in patients with advanced solid tumors. Exicure is in Chicago, IL and has an office in Cambridge, MA.

For more information, visit Exicure’s website at www.exicuretx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005074/en/

Contacts

Karen Sharma
MacDougall
781-235-3060
ksharma@macbiocom.com